 |
| Kem Hospital |
Kem Hospital of Mumbai will be one of the 10 centres in India, that will host phase II and phase III testing and trials of Covidshield, a Covid-19 vaccine developed at Oxford University.
The trials will begin in a week and will be conducted on 1,600 people across the ten centres of India which also includes 160 from Kem Hospital.
Dr Hemant Deshmukh, the dean of Kem Hospital said that he was informed by the ICMR that Kem was one of the centres where the trials would be conducted.
He said "The Vaccine is being manufactured by the Serum Institute of India(SII) in Pune and will be tested on 160 individuals At Kem Hospital." The state ethics committee processed this proposal to conduct trails here(Kem Hospital) he added.
The Hospital will now invite 160 healthy people between the age of 20 to 50 who have not contracted Covid-19 for trials. The candidates will also be from a range of social-economic background. Those who are found to have Covid-19 antibodies will not be eligible for the trails.
The results of the phase I trials of the vaccines have been good and have seen development of strong immune response. It has provoked a T-Cell which can fight CoronaVirus affected cells in the body within 14 days of Vaccination.
0 Comments